Effects of hyperprolactinemia on osteoporotic fracture in premenopausal women

Vartej, Petrache; Poiană, Cătălina; Vartej, Ioana

doi:10.1080/gye.15.1.43.47

Cited by 30 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies in patients with hyperprolactinaemia secondary to prolactinomas have found high rates of osteopenia and osteoporosis (Vartej et al , ; Colao et al , ; Kayath et al , ). Prolactin regulates the secretion of gonadotrophins and hence influences the levels of the gonadal hormones oestradiol and testosterone.…”

Section: Introductionmentioning

confidence: 99%

Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications

Crews

Howes

2012

Human Psychopharmacology

View full text Add to dashboard Cite

Objective-Osteoporosis is increasingly common worldwide and there is growing concern that the long-term use of antipsychotic medications increases the risk of this disorder. In this review we consider whether antipsychotics may contribute to the development of osteoporosis through reductions in bone mineral density (BMD), discuss the possible mechanisms involved and consider the clinical implications of such a relationship. Methods-We searched the literature for studies in this area published between 1966 and 2010 using the Medline and PubMed databases and the following search terms: (schizophrenia OR antipsychotic OR neuroleptic) AND (osteoporosis OR hyperprolactinaemia OR bone mineral density).Results-The available data indicates that statistically significant reductions in bone mineral density are frequently seen in patients prescribed antipsychotic medications and suggests that there is a higher incidence of clinically significant reductions compared with the normal population.Conclusions-Clinicians should be aware for the potential negative effects of antipsychotic medications on bone mineral density, particularly in patients with additional risk factors for osteoporosis. Recommendations regarding routine monitoring of bone mineral density for patients prescribed antipsychotic medications cannot be made on the basis of existing evidence and more research is required. Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications

show abstract

Section: Introductionmentioning

confidence: 99%

Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications

Crews

Howes

2012

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Untreated hyperprolactinemia can also lead to premature osteoporosis in both sexes due to impairment of gonadal function leading to a relative estrogen or testosterone deficiency. 51,57,60,73,146 These important, but often overlooked effects of hyperprolactinemia are additional arguments for treating patients who may not be concerned about sexual dysfunction. The osteopenia is progressive and correlates with the duration of hypogonadism.…”

mentioning

confidence: 99%

Contemporary management of prolactinomas

Liu

Couldwell²

2004

FOC

View full text Add to dashboard Cite

Prolactin-secreting pituitary adenomas—prolactinomas—are the most common type of functional pituitary tumor. Treatment of hyperprolactinemia is indicated because of the consequences of infertility, gonadal dysfunction, and osteoporosis. Making the correct diagnosis is important because the first line of therapy is medical management with dopamine agonists. Medical therapy is effective in normalizing prolactin levels in more than 90% of patients, but long-term treatment may be required in some patients. Transsphenoidal surgery is usually indicated in those patients in whom medical therapy fails or cannot be tolerated, or in patients who harbor microprolactinomas. In experienced hands, a hormonal and oncological cure can be achieved in more than 90% of patients after transsphenoidal removal of microprolactinomas with minimal risks. Thus, surgery may be an option for microprolactinomas in a young patient who desires restoration of fertility and avoidance of long-term medical therapy. The authors review the diagnosis and management of prolactinomas, including medical therapy, surgical therapy, and stereotactic radiosurgery.

show abstract

“…Treatment with bone density increases but may not return to the old level. In men with prolactinoma, osteopenia / osteoporosis occurs due to low testosterone levels [8][9][10][11][12] (Table 1). The pathogenesis of osteoporosis in patients with Cushing's disease, decreased osteoblast function, decreased calcium absorption from the bowel, calcium excretion from kidneys decreased gonadal steroid synthesis, decreased muscle mass and strength, growth hormone secretion and decreased effectIn cushing's disease, osteoporosis was found in 50% of the patients.…”

Section: Discussionmentioning

confidence: 99%

25-OH Vitamin D Levels in Patients with Pituitary Adenoma

Özçelik

Çelık²

2019

BJSTR

View full text Add to dashboard Cite

Of the 88 patients with pituitary adenoma, 62 (70.4%) had vitamin D deficiency, and 19 (21.6%) had vitamin D insufficiency.Only 7 patients (8%) had vitamin D levels above 30 ng / dl and were adequate. The mean age of the patients with non-functional adenoma was 41.7 years (min: 18-max: 68); 7 (33.3%) were males and 13 (61.9%) were females. In 15 patients, vit D was < 20, while 6 patients had vit D value of ≥20-<30. The mean age of patients with acromegaly was 46.1 years (min: 33-max: 64); 6 (54.5%) were males and 5 (45.5%) were females. In 8 patients, vit D was <20,

show abstract

Effects of hyperprolactinemia on osteoporotic fracture in premenopausal women

Cited by 30 publications

References 10 publications

Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications

Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications

Contemporary management of prolactinomas

25-OH Vitamin D Levels in Patients with Pituitary Adenoma

Contact Info

Product

Resources

About